Familial Amyloid Polyneuropathy Therapeutic Market

Familial Amyloid Polyneuropathy (FAP) is?a progressive, disabling and life-threatening polyneuropathy affecting the peripheral and autonomic nervous system. FAP is an autosomal transmission disorder which is usually due to a point mutation of the transthyretin (TTR) gene.The treatment of familial amyloid polyneuropathies (FAP) is complex and requires a neurological and cardiological multidisciplinary coverage. It includes specific treatments to control the progression of the systemic amyloidogenesis, the symptomatic treatment of the peripheral and autonomic neuropathy (digestive, urinary, sexual, postural hypotension) and the treatment of organs severely involved by amyloidosis (heart, eyes, kidneys).
Familial Amyloid Polyneuropathy Therapeutic Market contains market size and forecasts of Familial Amyloid Polyneuropathy Therapeutic in Global, including the following market information:
Global Familial Amyloid Polyneuropathy Therapeutic Market Revenue, 2018-2023, 2023-2030, ($ millions)
Global top five companies in 2022 (%)
The global Familial Amyloid Polyneuropathy Therapeutic market was valued at US$ million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period 2023-2030.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million by 2030.
Inotersen Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Familial Amyloid Polyneuropathy Therapeutic include Pfizer Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Corino Therapeutics Inc., Proclara Biosciences and Arcturus Therapeutics Inc, etc. In 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Familial Amyloid Polyneuropathy Therapeutic companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Familial Amyloid Polyneuropathy Therapeutic Market, by Drug Type, 2018-2023, 2023-2030 ($ millions)
Global Familial Amyloid Polyneuropathy Therapeutic Market Segment Percentages, by Drug Type, 2022 (%)
Inotersen
Tafamidis
Patisiran
Others
Global Familial Amyloid Polyneuropathy Therapeutic Market, by Application, 2018-2023, 2023-2030 ($ millions)
Global Familial Amyloid Polyneuropathy Therapeutic Market Segment Percentages, by Application, 2022 (%)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Global Familial Amyloid Polyneuropathy Therapeutic Market, By Region and Country, 2018-2023, 2023-2030 ($ Millions)
Global Familial Amyloid Polyneuropathy Therapeutic Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Familial Amyloid Polyneuropathy Therapeutic revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Familial Amyloid Polyneuropathy Therapeutic revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer Inc.
Alnylam Pharmaceuticals Inc.
Ionis Pharmaceuticals Inc.
Corino Therapeutics Inc.
Proclara Biosciences
Arcturus Therapeutics Inc